Slovakia Pharmaceuticals and Healthcare Report Q2 2016

92 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Improving domestic economic outlook will provide a boost to healthcare expenditure in
Slovakia in the short term. Over the longer term, we expect healthcare spending to accelerate, given
Slovakia’s ageing population and burden of chronic diseases. With public finances on a firmer footing and a
centre-left government promising more generous social spending, multinational drugmakers and medical
device companies can expect to see growth in revenues from Slovakia.
Headline Expenditure Projections
? Pharmaceuticals: EUR1.91bn (USD2.10bn) in 2015 to EUR1.97bn (USD2.12bn) in 2016; +2.8% in
local currency terms and +0.6% in US dollar terms. Forecast revised slightly downwards from last
quarter.
? Healthcare: EUR6.27bn (USD6.89bn) in 2015 to EUR6.45bn (USD6.94bn) in 2016; +2.9% in local
currency terms and +0.7% in US dollar terms. Forecast revised slightly downwards from last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Slovakia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2012-2020) 13
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Members Of GENAS, 2015 25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 26
OTC Medicine Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020) 29
Pharmaceutical Trade Forecast 30
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2014-2020) 32
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2014-2020) 32
Industry Risk/Reward Index 33
Central And Eastern Europe Risk/Reward Index 33
Slovakia Risk/Reward Index 39
Rewards 39
Risks 39
Regulatory Review 41
Regulatory Regime 41
Intellectual Property Issues 44
Pricing Regime 45
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 46
Reimbursement Regime 47
Market Overview 52
Healthcare Sector 53
Table: Healthcare Resources (Slovakia 2010-2015) 55
Table: Healthcare Personnel (Slovakia 2010-2015) 55
Table: Healthcare Activity (Slovakia 2010-2015) 56
Research And Development 60
Table: Members Of BITCET, 2011 61
Table: Members Of SLOVBIOTECH, 2010 62
Clinical Trials 63
Epidemiology 64
Table: Main Causes Of Mortality And Morbidity In Slovakia 65
Competitive Landscape 67
Research-Based Industry 67
Table: Members Of SAFS, 2012 67
Table: Multinational Market Activity 68
Generic Drugmakers 69
Table: Registered Pharmaceutical Manufacturers 69
Pharmaceutical Distribution 70
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated) 71
Pharmaceutical Retail Sector 71
Company Profile 74
Biotika 74
HBM Pharma 76
Imuna Pharma 79
Demographic Forecast 81
Table: Population Headline Indicators (Slovakia 1990-2025) 82
Table: Key Population Ratios (Slovakia 1990-2025) 82
Table: Urban/Rural Population & Life Expectancy (Slovakia 1990-2025) 83
Table: Population By Age Group (Slovakia 1990-2025) 83
Table: Population By Age Group % (Slovakia 1990-2025) 84
Glossary 86
Methodology 88
Pharmaceutical Expenditure Forecast Model 88
Healthcare Expenditure Forecast Model 88
Notes On Methodology 89
Risk/Reward Index Methodology 90
Index Overview 91
Table: Pharmaceutical Risk/Reward Index Indicators 91
Indicator Weightings 92

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Slovakia 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Members Of GENAS, 2015
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Slovakia 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Slovakia 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Slovakia 2014-2020)
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia
Table: Healthcare Resources (Slovakia 2010-2015)
Table: Healthcare Personnel (Slovakia 2010-2015)
Table: Healthcare Activity (Slovakia 2010-2015)
Table: Members Of BITCET, 2011
Table: Members Of SLOVBIOTECH, 2010
Table: Main Causes Of Mortality And Morbidity In Slovakia
Table: Members Of SAFS, 2012
Table: Multinational Market Activity
Table: Registered Pharmaceutical Manufacturers
Table: ADL Members, 2012 (Manufacturers, unless otherwise indicated)
Table: Population Headline Indicators (Slovakia 1990-2025)
Table: Key Population Ratios (Slovakia 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Slovakia 1990-2025)
Table: Population By Age Group (Slovakia 1990-2025)
Table: Population By Age Group % (Slovakia 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Slovakia Pharmaceuticals and Healthcare Report Q3 2015BMI View: Eurozone recovery and an improving domestic economic outlook will provide a boost to healthcare expenditure in Slovakia in the short-term. Over the longer term, we expect healthcare spending to accelerate given Slovakia's ageing population and burden of chronic diseases. With public finances on firmer footing and a centre-left government promising more generous social spending, multinational drugmakers and medical device companies can expect to see growth in revenues from […]
  • Hong Kong Pharmaceuticals and Healthcare Report Q2 2016BMI View: The ageing of Hong Kong's demography will necessitate changes to its healthcare system. Top of the agenda will be healthcare financing, as authorities face rising medical costs as chronic diseases rise and tax revenues decline due to the rising dependency ratio. Similarly, healthcare delivery will be a key area of focus as the special administrative region augments the existing medical resources to cope with demand. Headline Expenditure Projections ? Pharmaceuticals: […]
  • Poland Pharmaceuticals and Healthcare Report Q2 2016BMI View: The impending shift to a tax-based healthcare system will provide enticing revenue earning opportunities for multinational pharmaceutical firms operating in Poland, while the country's increasing pensionable population will drive demand in high-value medicines for the treatment of chronic diseases, such as cancer and cardiovascular diseases. However, the government's ambitious spending initiatives risk overstretching finances in the future, forcing it to moderate a number […]
  • Netherlands Pharmaceuticals and Healthcare Report Q1 2016BMI View: The Netherlands has a well-developed healthcare system due to generous public expenditure over the years. Despite newly introduced cost-cutting measures, government spending on healthcare will continue to increase in local currency terms, especially as the wider eurozone recovers. However, the country's aging population will put pressure on government finances over the longer-term, inevitably leading to further price caps on medicines. Headline Expenditure Projections ? […]
  • Colombia Pharmaceuticals and Healthcare Report Q2 2016BMI View: A growing burden of chronic diseases, along with the Colombian government's push toward improving health coverage, will ensure the country's retained appeal to multinational drugmakers and healthcare suppliers. However, inefficiencies and debt within healthcare provision will fuel instability in the healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: COP9,101bn (USD3.31bn) in 2015 to COP9,584bn (USD2.92bn) in 2016; +5.3% in local currency and -12.0% in US […]